Spyre TherapeuticsFRA:3920 -2.56%33 Current Ratio is 8.97 as of Mar. 2026, which is 3% above its 10-year median of 8.72. GuruFocus rates FRA:3920 with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Spyre Therapeutics ranks better than 74.63% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Spyre Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 8.97.
Spyre Therapeutics has a current ratio of 8.97. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Spyre Therapeutics's Current Ratio or its related term are showing as below:
FRA:3920'
s Current Ratio Range Over the Past 10 Years
Min: 1.03 Med: 8.72 Max: 22.88
Current: 8.97
During the past 13 years, Spyre Therapeutics's highest Current Ratio was 22.88. The lowest was 1.03. And the median was 8.72.
FRA:3920's Current Ratio is ranked better than 74.63% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs FRA:3920: 8.97
Spyre Therapeutics (FRA:3920) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Spyre Therapeutics Current Ratio Related Terms
Spyre Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Spyre Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3920 vs MIRM, RYTM, PTGX: Current Ratio Comparison
For the Biotechnology subindustry, Spyre Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics (FRA:3920) has a Current Ratio of 8.97 as of Mar. 2026. This is near median its historical median of 8.72. Over the past decade, Spyre Therapeutics' Current Ratio has ranged from 1.03 to 22.88. According to the industry distribution chart, Spyre Therapeutics ranks #358 out of 1411 companies in the Biotechnology industry, placing it in the top 25.4%.
Is Spyre Therapeutics' Current Ratio too high?
Spyre Therapeutics' current Current Ratio of 8.97 is near median its 10-year median of 8.72. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 22.88. The Biotechnology industry median Current Ratio is 3.91. Spyre Therapeutics' value of 8.97 is 129.4% above this industry median. Based on the distribution chart, Spyre Therapeutics ranks #358 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spyre Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Current Ratio compare to MIRM and RYTM?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #358 out of 1411 companies for Current Ratio. This puts Spyre Therapeutics in the upper half of its industry. The industry median Current Ratio is 3.91. Spyre Therapeutics' value of 8.97 is 129.4% above this benchmark. Historically, Spyre Therapeutics' own Current Ratio has ranged from 1.03 to 22.88 over the past decade. While the company's 10-year median is 8.72 vs. the industry median of 3.91, Spyre Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spyre Therapeutics's current Current Ratio of 8.97 is 129.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current Current Ratio is 8.97, which is near median its own 10-year median of 8.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (FRA:3920) has a current Current Ratio of 8.97. The current Current Ratio is 8.97, which is near median its 10-year median of 8.72 and 129.4% above the Biotechnology industry median of 3.91. Spyre Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current Current Ratio is 8.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
33GF Score
Get the complete analysis for FRA:3920
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3920 has been successfully added to your 
